Application of osteopontin and Stathmin-1 expression in the evaluation of prostate cancer recurrence and survival prognosis

Objective To explore the application of osteopontin (OPN) and Stathmin-1 expression in the evaluation of prostate cancer recurrence and survival prognosis. Methods One hundred patients with prostate cancer were selected from June 2014 to June 2016. The expressions of OPN and Stathmin-1 in prostate cancer tissue were detected by immunohistochemical staining SP method, and its correlation with clinicopathological features was analyzed. Results The OPN positive expression in prostate cancer tissue was in 76 cases (76.00%, 76/100), the Stathmin-1 positive expression in prostate cancer tissue was in 79 cases (79.00%, 79/100), and both the OPN and Stathmin-1 positive expression in prostate cancer tissue was in 60 cases (60.00%, 60/100). Spearman correlation analysis result showed that the expression of OPN in prostate cancer tissue had positive correlation with Stathmin-1 (r= 0.491, P 0.05). The survival time in OPN positive expression, Stathmin-1 positive expression and both OPN/Stathmin-1 positive expression was (18.45 ± 2.03), (17.95 ± 2.01) and (15.24 ± 1.72) months; the survival time in OPN negative expression, Stathmin-1 negative expression and OPN/Stathmin-1 single positive or both negative was (24.67 ± 2.62), (23.79 ± 2.58) and (26.68 ± 2.72) months, and there was statistical difference (P<0.05). Conclusions The OPN and Stathmin-1 expressions in prostate cancer tissue are high, and show relations with Gleason score, bone metastases and T staging, and no correlation with recurrence. But OPN and Stathmin-1 can provide reference for survival in patients with prostate cancer prognosis assessment. Key words: Prostatic neoplasms; Osteopontin; Recurrence; Prognosis; Retrospective studies